Core Insights - Agenus Inc. has appointed José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025 [1] - Dr. Iglesias will oversee global medical affairs for botensilimab (BOT) and balstilimab (BAL) as they progress through Phase 3 evaluation [1] - The combination of BOT and BAL will be made available in selected countries through early-access mechanisms, including France's Autorisation d'Accès Compassionnel [1]

Core Insights - Agenus Inc. will host a virtual Stakeholder Briefing on October 21, 2025, focusing on updates regarding its immunotherapy combination botensilimab (BOT) and balstilimab (BAL) [1][3] - The briefing will feature insights from leading experts on recent clinical progress and expanding international access for BOT/BAL, moderated by Garo Armen, PhD, the company's CEO [1][3] Company Overview - Agenus is a leader in immuno-oncology with a comprehensive pipeline of immunological agents, founded in 1994 [4] - The company aims to expand patient populations benefiting from cancer immunotherapy through combination approaches, utilizing a variety of therapeutic methods [4] Product Information - Botensilimab (BOT) is designed to enhance anti-tumor immune responses and is effective in treating "cold" tumors that typically respond poorly to standard therapies [5][6] - Approximately 1,200 patients have been treated with BOT/BAL in phase 1 and phase 2 clinical trials, showing clinical responses across nine metastatic, late-line cancers [7] - Balstilimab (BAL) is a fully human monoclonal antibody that blocks PD-1 interactions, demonstrating clinical activity in over 900 patients [8]